Skip to content
TrialMatch
Sign up
Recruiting

A Cohort Study in Newly Diagnosed MZL

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Condition
Marginal Zone Lymphoma
Tested
patients receive optimal treatment or follow-up according to the characteristics of the disease
Sponsor
Fudan University

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 7

  • Minimum age: 18 years
  • Study condition: Marginal Zone Lymphoma
  • Ageā‰„ 18 years old; Male or female.
  • Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors).
  • Willing to provide biological samples required for the study, including blood samples and tumor tissue.
  • Voluntarily join this study and sign the informed consent form.
  • Willing to accept long-term follow-up.

Exclusion 3

  • Patients with HIV infection.
  • Those who cannot come to the hospital regularly for follow-up.
  • Those with comorbidities and speech impairment.

Where

1 site, 1 recruiting

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.